Practice materials
Our online library of practice materials offers downloadable resources, including patient profiles, details about clinical data, and forms for your staff.
Information and data about MIEBO
KALAHARI Flashcard
This flashcard summarizes the outcomes of the 52-week KALAHARI study, an analysis of the long-term safety and efficacy of MIEBO.
In Vitro Evaporation Flashcard
This flashcard provides results from an in vitro study evaluating evaporation rates with MIEBO.
Clinical Data Deep Dive Whitepaper
This whitepaper explores clinical findings from the KALAHARI, GOBI, and MOJAVE studies in a comprehensive data summary, including key trial designs, endpoints, and results.
BlinkRx ECP Leave Behind
Learn how to prescribe through BlinkRx and explore a brief overview of how BlinkRx can help patients with their MIEBO prescriptions.
Patient forms
MIEBO Prior Authorization (PA) Checklist
This guide can help you complete a PA request for MIEBO and ensure necessary information is provided to the payer. It also includes a list of diagnosis code examples.
BlinkRx Patient Instruction Tearpad (Commercial and Government)
These resources inform patients about BlinkRx and what to expect when you send your patient prescriptions through this program. There are 2 versions: one for commercial patients under 65 and one for government patients (including those covered by Medicare Part D).
BlinkRx Fax Form
This form is used to e-prescribe MIEBO to BlinkRx. For more details, see BlinkRx information above.
INDICATION
MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
- MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane
- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established
- In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)
Click here for full Prescribing Information for MIEBO.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
You are now leaving MIEBO-ECP.COM
You are now leaving the MIEBO ECP website and are going to a website that Bausch + Lomb does not operate and to which Bausch + Lomb’s Privacy Policy does not apply.
Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to visit and does not endorse or monitor any content on such website.
INDICATION AND IMPORTANT
SAFETY INFORMATION
INDICATION
MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
- MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane
- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established
- In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)
Click here for full Prescribing Information for MIEBO.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.